Mitochondrial Dysfunction Increases Arrhythmic Triggers and Substrates; Potential Anti-arrhythmic Pharmacological
Khalil Saadeh1,2, Ibrahim Talal Fazmin1,2,3
1School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.
Frontiers in Cardiovascular Medicine
|March 4, 2021
Summary
Aging hearts face increased arrhythmia risk due to mitochondrial dysfunction. Targeting mitochondrial health offers new strategies for preventing cardiac arrhythmias in older adults.
Area of Science:
- Cardiology
- Mitochondrial Biology
- Geriatrics
Background:
- Cardiac arrhythmias incidence rises with age.
- Age-related electrophysiological disruption is linked to mitochondrial dysfunction.
- Understanding molecular mechanisms is key for risk stratification in aging populations.
Purpose of the Study:
- To review mechanisms linking age-related mitochondrial dysfunction to cardiac arrhythmias.
- To explore novel anti-arrhythmic therapies targeting mitochondrial function.
Main Methods:
- Literature review of studies on aging, mitochondrial dysfunction, and cardiac arrhythmias.
- Analysis of molecular pathways affected by mitochondrial dysfunction.
- Discussion of potential pharmacological interventions.
Main Results:
- Age-related mitochondrial dysfunction alters ionic currents, gap junctions, calcium homeostasis, and promotes fibrosis.
- These changes create triggers and substrate for arrhythmias.
- Targeting upstream mitochondrial function may offer a novel therapeutic approach.
Conclusions:
- Mitochondrial dysfunction is a key driver of age-related cardiac arrhythmias.
- Stratifying patients by mitochondrial function can guide therapy.
- Novel therapies targeting mitochondrial function hold promise for treating arrhythmias in the elderly.
More Related Videos
Related Concept Videos
Electron Transport Chain: Complex I and II
16.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
16.9K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.5K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.5K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.2K
Mechanism of Cardiac Arrhythmias
1.4K
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
1.4K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.1K
Dysrhythmias VI: Management of Dysrhythmias
213
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
213


